It is a weight-loss medication in the form of a pen injector, containing the active ingredient Liraglutide
Domperidone (10 mg up to three times daily) is an alternative prokinetic agent but has MHRA restrictions due to cardiac risks (QT prolongation) and interactions with CYP3A4 inhibitors
The CagriSema metabolic preservation mechanism, specifically the maintenance of mitochondrial function in skeletal muscle during weight loss, could theoretically slow the rate of weight regain by preventing some of the metabolic adaptation that makes regain almost inevitable
Additionally, the suppression of pro-inflammatory cytokines (e.g., TNF-, IL-6) and inflammatory pathways, including the blocking of NF-B activation [39, 91], contributes to the establishment of an anti-inflammatory environment that can mitigate oxidative stress and inflammation induced muscle protein catabolism, thereby supporting the preservation of SMM and functional capacity [40]
Neither approach is inherently superior